Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic ...
KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of ...
Keymed Biosciences Inc.: Keymed Biosciences Announces Approval of Stapokibart For the ...
Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental ...
Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and ...
Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of ...
Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Recently Announced Preliminary ...
Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities ...